Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.

However, the SYSUCC-002 trial has limitations in that the hazard ratio upper bound defining non-inferiority was rather modest (1.35) and the trial did not incorporate pertuzumab in the first-line HER2+ metastatic setting, which is the current standard of care (based upon a large and highly significant OS advantage in first-line HER2+ metastatic disease in the CLEOPATRA trial 84 ) and only a minority of patients in SYSUCC-002 were assigned to taxane chemotherapy in the control arm.

also in 132,142 other papers